Table of Content

1 Market Introduction
1.1 Market Definition
1.2 Research Scope and Segmentation
1.3 Stakeholders
1.4 List of Abbreviations


2 Executive Summary


3 Research Methodology
3.1 Identification of Data
3.2 Data Analysis
3.3 Verification
3.4 Data Sources
3.5 Assumptions


4 Market Dynamics
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges


5 Porter’s Five Force Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Buyers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry in the Market


6 Global Oncology Clinical Trials Market by, Phase Type
6.1 Overview
6.2 Phase I
6.3 Phase II
6.4 Phase III
6.5 Phase IV


7 Global Oncology Clinical Trials Market by, Study Design
7.1 Overview
7.2 Interventional Studies
7.3 Observational Studies
7.4 Expanded Access Studies


8 Global Oncology Clinical Trials Market by, Cancer Type
8.1 Overview
8.2 Breast Cancer
8.3 Leukemia
8.4 Lung Cancer
8.5 Prostate Cancer
8.6 Other Cancer Types


9 Global Oncology Clinical Trials Market by, Geography
9.1 Overview
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 South Korea
9.4.5 Australia
9.4.6 New Zealand
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 UAE
9.6.2 Saudi Arabia
9.6.3 Qatar
9.6.4 Iran
9.6.5 South Africa
9.6.6 Rest of Middle East & Africa


10 Key Developments


11 Company Profiling
11.1 AbbVie Inc.
11.1.1 Business Overview
11.1.2 Product/Service Offering
11.1.3 Financial Overview
11.1.4 SWOT Analysis
11.1.5 Key Activities
11.2 Astellas Pharma Inc.
11.3 AstraZeneca
11.4 Bristol Myers Squibb
11.5 Eli Lilly and Company
11.6 F. Hoffmann-La Roche Ltd
11.7 GlaxoSmithKline
11.8 Johnson & Johnson
11.9 Merck & Co.
11.10 Novartis
11.11 Pfizer Inc.
11.12 Sanofi